

A randomized controlled trial of the effect of preoperative dexmedetomidine on the half maximal effective concentration of propofol for successful i-gel insertion without muscle relaxants

Young-Eun Jang · Yong-Chul Kim · Hyun-Kyu Yoon ·
Young-Tae Jeon · Jung-Won Hwang · Eugene Kim ·
Hee-Pyoung Park

Received: 25 July 2014 / Accepted: 30 October 2014 / Published online: 14 November 2014
© Japanese Society of Anesthesiologists 2014

Abstract

Background Dexmedetomidine is a useful anesthetic adjuvant for general anesthesia. We determined whether preoperative dexmedetomidine administration could reduce the half maximal effective concentration (EC₅₀) of propofol for successful i-gel insertion without muscle relaxants.

Methods Thirty-seven patients were randomly allocated to one of two groups. In the dexmedetomidine group ($n = 19$), dexmedetomidine (1 $\mu\text{g}/\text{kg}$) was loaded for 10 min preoperatively. In the control group ($n = 20$), the same volume of 0.9 % normal saline was administered in the same manner. The EC₅₀ of propofol for successful i-gel insertion was determined using Dixon's up-and-down method. The EC₅₀ of propofol was calculated as the mid-point concentration after at least six crossover points had been obtained. For successful i-gel insertion, all of the following four factors were required—(1) no major movement of the body within 1 min of insertion, (2) no significant resistance to mouth opening, (3) cough ≤ 2 , and (4) visible square wave capnogram without air leakage at a peak airway pressure of <10 cmH₂O. Mean blood pressure (MBP)

and heart rate (HR) were monitored during the peri-insertion period of i-gel.

Results The EC₅₀ of propofol for successful i-gel insertion was 3.18 $\mu\text{g}/\text{mL}$ in the dexmedetomidine group and 6.75 $\mu\text{g}/\text{mL}$ in the control group ($p < 0.001$). The incidence of hypotension (MBP <80 % of the baseline) during the peri-insertion period of i-gel was higher in the control group ($p = 0.001$), whereas the incidence of bradycardia (HR <80 % of the baseline) was higher in the dexmedetomidine group ($p = 0.001$).

Conclusions Preoperative dexmedetomidine reduced the EC₅₀ of propofol for successful i-gel insertion without muscle relaxants.

Keywords Dexmedetomidine · i-gel · Propofol

Introduction

The i-gel (Intersurgical Ltd., Wokingham, UK) is a non-reusable supraglottic airway device that has a unique advantage over laryngeal mask airway (LMA) devices with respect to insertion. Specifically, the i-gel has a soft, bulky, non-inflatable cuff. Therefore, an appropriate anatomic seal for the supraglottic airway can be accomplished without air inflation. The effectiveness of i-gel for airway management has been reported in patients with out-of-hospital cardiac arrest and in those with difficult airways in the operating room [1–6].

Propofol is a useful induction agent for supraglottic airway device insertion without muscle relaxants because it profoundly inhibits pharyngeal and laryngeal reactivity [7, 8]. A previous report showed that the effect-site concentration of propofol for successful classic LMA insertion in 50 % of adults (EC₅₀) without muscle relaxants in healthy

Trial Registration Identifier: NCT02097407 (<http://www.clinicaltrials.gov>).

Y.-E. Jang · Y.-C. Kim · H.-K. Yoon · E. Kim · H.-P. Park (✉)
Department of Anesthesiology and Pain Medicine,
Seoul National University Hospital, Seoul National
University College of Medicine, 101 Daehak-ro,
Jongno-gu, Seoul 110-744, South Korea
e-mail: hppark@snu.ac.kr

Y.-T. Jeon · J.-W. Hwang
Department of Anesthesiology and Pain Medicine, Seoul
National University Bundang Hospital, Seoul National University
College of Medicine, Seongnam, South Korea

Table 1 The i-gel™ insertion conditions

| Condition | Patient response |
|-----------|--|
| Excellent | Lack of movement of the body or limbs within 1 min of insertion, no cough or gagging, and good jaw relaxation |
| Good | Minor movement of the body, such as finger movement within 1 min of insertion, and good jaw relaxation and one or two coughs or gags |
| Difficult | Major movement of the body or limbs within 1 min of insertion or >2 coughs or gags, or severe resistance of mouth opening |

Difficult i-gel insertion condition is considered as failure

male patients was 8.72 (0.55) $\mu\text{g mL}^{-1}$ [9]. The EC_{50} of propofol may be dependent on the type of supraglottic airway device used. A previous study comparing the EC_{50} of the propofol concentration between classic and proseal LMA insertions demonstrated that the EC_{50} of propofol needed for Pro-Seal LMA insertion was 35 % greater than that needed for classic LMA insertion [10]. Unfortunately, no investigation has been performed to determine the EC_{50} of the propofol concentration required for i-gel insertion without muscle relaxants.

Dexmedetomidine (DEX), a highly selective alpha-2 agonist, has sympatholytic, sedative, and analgesic properties. Such beneficial characteristics make DEX a useful anesthetic adjuvant for general anesthesia. Many reports have revealed the beneficial effects of DEX in terms of reducing airway secretion, hemodynamic response to noxious stimuli such as endotracheal intubation, intraoperative anesthetic requirements, and postoperative analgesic demand [11–16]. A previous investigation showed that preoperative clonidine, an alpha-2 agonist, decreased the EC_{50} required for LMA insertion [9]. However, there is no study concerning the effect of preoperative DEX on the EC_{50} of propofol needed for successful i-gel insertion.

We hypothesized that preoperative DEX administration can reduce the propofol concentration required for i-gel insertion. We conducted this study to find the EC_{50} of propofol needed for successful i-gel insertion without muscle relaxants and to determine the effect of preoperative DEX administration on the EC_{50} of propofol.

Methods

Setting and study design

After obtaining approval from the Institutional Review Board (IRB) of Seoul National University Hospital (number H-1203-041-400) and written informed consent from patients, we prospectively enrolled 39 American Society of Anesthesiologist (ASA) physical status I–II patients who were aged 20–65 years and scheduled for general anesthesia for minor urologic surgery between May and August 2012. Patients with an allergy to alpha-2 adrenergic

agonists or propofol, anticipated difficult airway (cervical spinal disease, Mallampati score of III or IV, a mouth opening of <2.5 cm, and/or body mass index of >30 kg/m), unstable teeth, bradycardia of <50 beats/min, heart block greater than first degree, severe cardiorespiratory dysfunction, and symptoms of upper respiratory infection were excluded. The protocol for this clinical trial was registered at ClinicalTrials.gov (NCT02097407).


Group assignment

Patients were randomly allocated to one of two groups. Randomization was accomplished using random computer-generated numbers. The assignments were concealed in opaque envelopes and opened immediately before induction by a nurse who was blinded to this study and responsible for preparing the study drugs. In Group D, DEX (1 $\mu\text{g}/\text{kg}$) was intravenously loaded over 10 min before induction of anesthesia. In Group C, the same volume of 0.9 % normal saline was administered in the same manner.

Study protocol

All patients were pre-oxygenated with 100 % oxygen with spontaneous breathing for 3 min before the end of loading of DEX or normal saline. Anesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C and D received an effect-site propofol concentration of 5 and 3 $\mu\text{g}/\text{mL}$, respectively. We used the Schnider pharmacokinetic model ($k_{e0} = 0.46/\text{min}$) for propofol [17]. After achieving equilibration of the plasma and effect-site propofol concentrations and confirming adequate anesthetic level, i-gel (size 4 for patients weighing 50–90 kg, size 3 for patients weighing 30–50 kg) was inserted using the standard technique by a single anesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment. The i-gel insertion condition was classified by the anesthesiologist staff as excellent, good or difficult according to body movement, coughing, gagging, and jaw mobility (Table 1) [18]. If the patient shows an inadequate anesthetic level such

Fig. 1 Flow chart for the Dixon up-and-down method



as a high BIS of >60 or intact eyelid reflex before i-gel insertion, it was regarded as ‘failure’, and additional propofol was administered to deepen the level of anesthesia. If we experienced difficult insertion conditions of the i-gel, it was also regarded as ‘failure’, and propofol was administered additionally after i-gel insertion. For ‘successful’ i-gel insertion, both of the following two factors are required—(1) excellent or good i-gel insertion condition and (2) visible movement of the chest and serial square wave capnograph trace without air leakage at a peak airway pressure of <10 cm H₂O [19]. Furthermore, the presence of laryngospasm and the number of external airway manipulations was noted.

The EC₅₀ of propofol for successful i-gel insertion was determined by a modification of Dixon’s up-and-down method [20–22]. A flow chart for the Dixon up-and-down method in this study is shown in Fig. 1. The response of each patient determined the effect-site propofol concentration for the next patient. If the response was deemed ‘successful’, the next target concentration of propofol was decreased by 0.5 µg/mL. If the response was deemed a ‘failure’, the target concentration was increased by the

same dose. The process was repeated until at least the sixth crossover point (success/failure) was obtained.

After removing the i-gel, airway trauma (defined as any blood staining on the device) was noted by a junior anesthesiologist resident blinded to this study.

Measurements

The insertion time, defined as the time from picking up the i-gel until the initiation of mechanical ventilation, was recorded. The mean blood pressure (MBP), heart rate (HR), and bispectral index (BIS) were measured immediately before loading (baseline) and every 2 min for the 10-min DEX or normal saline loading, every 1 min during the 5-min anesthetic induction, and 1, 2, and 3 min after i-gel insertion. Hypertension was defined as an MBP >20 % higher than the baseline value, whereas hypotension was defined as an MBP >20 % lower than the baseline value. Tachycardia was defined as a HR >20 % higher than the baseline value, whereas bradycardia was defined as a HR >20 % lower than the baseline value.




Fig. 2 Consecutive effect-site propofol concentrations for i-gel insertion in patients receiving preoperative dexmedetomidine (group D) or saline (group C)

Table 2 Patient characteristics

| Variables | Group C (n = 20) | Group D (n = 19) | p-value |
|--------------------------|------------------|------------------|---------|
| Male gender | 15 | 18 | 0.182 |
| Age (years) | 41.2 (10.1) | 36.1 (11.3) | 0.146 |
| BMI (kg/m ²) | 24.1 (2.3) | 25.0 (3.1) | 0.328 |
| ASA class (I/II) | 17/3 | 17/2 | 1.000 |
| Mallampati class (I/II) | 16/4 | 15/4 | 1.000 |

Data are mean (SD) or number

Group C control group, Group D dexmedetomidine group

The primary measurement in this study was the EC₅₀ of propofol required for successful i-gel insertion. The secondary measurement was the presence of airway trauma after i-gel insertion.

Statistics

Pace and Stylianou reported that 20–40 subjects are generally needed in the Dixon up-and-down method, but when the sixth crossover point (success/failure) is achieved, no further subject enrolment is required [23]. The EC₅₀ of propofol was determined by calculating the mean of the midpoint concentration of all independent pairs of patients who manifested a crossover from a negative to a positive response (i.e., failure to success of insertion of i-gel) [20–22]. Probit analysis was used to calculate the 95 % confidence interval (CI) of the propofol EC₅₀ and EC₉₅ for successful i-gel insertion. The propofol EC₅₀ and demographics were analysed by an independent *t* test. Hemodynamic data and BIS values were subjected to repeated-measures ANOVA. If the difference between the two groups was significant, an independent *t* test was used to determine the difference at each time point. The

number of patients with blood-tinged i-gel, ASA class, hypotension, and bradycardia were analysed by chi-squared test or Fisher’s exact test as appropriate. A *p* value of <0.05 was considered to indicate statistical significance.

Results

Thirty-nine patients were enrolled in this study. Two patients in Group D showed an inadequate anesthetic level such as a high BIS of >60, spontaneous movement, and an intact eyelid reflex before i-gel insertion. At least six pairs of success–failure crossovers were obtained in 19 and 20 patients in Groups D and C, respectively (Fig. 2).

Patient characteristics between Groups D and C were not significantly different (Table 2). There were no significant differences in the responses of individual patients to i-gel insertion between the two groups (Table 3). No patient in either group showed laryngospasm during i-gel insertion, external airway manipulation during i-gel insertion, or blood-tinged airway equipment after removing i-gel.

The EC₅₀ of propofol for successful i-gel insertion, which was calculated from the modified Dixon up-and-down method, was 3.18 (0.35) µg/mL and 6.75 (0.55) µg/mL in Groups D and C, respectively (*p* < 0.001). The EC₅₀ and EC₉₅ of propofol for successful i-gel insertion, which were estimated from Probit analysis, were 3.01 µg/mL (95 % CI 2.57–3.51) and 3.70 µg/mL (95 % CI 3.37–7.14) in Group D and 6.75 µg/mL (95 % CI 6.17–8.02) and 7.78 µg/mL (95 % CI 7.17–16.14) in Group C, respectively.

Changes in MAP over time between the two groups differed markedly (*p* < 0.05, Fig. 3). MBP was significantly higher in Group D than in Group C from 4 min of propofol infusion until 3 min following i-gel insertion (*p* < 0.01). The number of patients with decreased MBP of >20 % of

Table 3 Data related to i-gel insertion

| | Success (<i>n</i> = 18) | | | Failure (<i>n</i> = 21) | | |
|----------------------|--------------------------|--------------------------|-----------------|--------------------------|-------------------------|-----------------|
| | Group C (<i>n</i> = 8) | Group D (<i>n</i> = 10) | <i>p</i> -value | Group C (<i>n</i> = 12) | Group D (<i>n</i> = 9) | <i>p</i> -value |
| Jaw mobility | | | | | | |
| Fully relaxed | 6 | 8 | 1.000 | 5 | 7 | 0.251 |
| Mild resistance | 2 | 2 | | 3 | 1 | |
| Tight but open | 0 | 0 | | 4 | 1 | |
| Closed | 0 | 0 | | 0 | 0 | |
| Cough | | | | | | |
| None | 8 | 10 | NM | 8 | 7 | 0.722 |
| 1–2 coughs | 0 | 0 | | 1 | 1 | |
| ≥3 coughs | 0 | 0 | | 3 | 1 | |
| Gag | | | | | | |
| None | 8 | 10 | NM | 6 | 5 | 1.000 |
| Yes | 0 | 0 | | 6 | 4 | |
| Body movement | | | | | | |
| None | 8 | 8 | 0.447 | 2 | 0 | 0.157 |
| Minor | 0 | 2 | | 2 | 0 | |
| Major | 0 | 0 | | 8 | 9 | |
| Insertion time (s) | 20.3 (4.4) | 21.5 (4.1) | 0.877 | 22.1 (5.8) | 20.0 (5.6) | 0.798 |
| Other events | | | | | | |
| Hypotension | 8 | 3 | 0.004 | 7 | 0 | 0.007 |
| Hypertension | 0 | 1 | 1.000 | 0 | 6 | 0.002 |
| Bradycardia | 0 | 7 | 0.004 | 3 | 8 | 0.008 |
| Tachycardia | 1 | 2 | 1.000 | 6 | 1 | 0.159 |
| Laryngospasm | 0 | 0 | NM | 0 | 0 | NM |
| Airway trauma | 0 | 0 | NM | 0 | 0 | NM |

Data are number or mean (SD)

Group C control group, Group D dexmedetomidine group, NM not measurable

the baseline value was higher in Group C than in Group D [15 (75 %) vs 3 (16 %), $p = 0.001$, Table 2]. Changes in HR over time between the two groups were markedly different ($p < 0.01$, Fig. 3). HR was significantly lower in Group D than in Group C after 8 min of loading; this difference was maintained after i-gel insertion ($p < 0.01$). The number of patients with decreased HR of >20 % of the baseline value was lower in Group C than Group D [3 (15 %) vs 15 (79 %), respectively; $p < 0.001$, Table 2]. However, no patient showed hypotension (MBP <60 mmHg) or severe bradycardia (HR <40 beats/min) during the entire study period in either group. Changes in the BIS over time were not different between the two groups.


Discussion

This is the first study to determine the EC₅₀ of the propofol concentration required for i-gel insertion without muscle relaxants in adult patients; we demonstrated that the EC₅₀

of propofol for successful i-gel insertion was 6.75 µg/mL and that preoperative DEX administration reduced the EC₅₀ of propofol by 53 %.

Different supraglottic airway devices can have different propofol concentrations of EC₅₀ needed for their insertion. The EC₅₀ of propofol required for successful insertion of classic LMA is 6.5–8.7 µg/mL [9, 24–26]. Interestingly, a previous study demonstrated that the EC₅₀ of propofol needed for successful Pro-Seal LMA insertion was 38 % greater than that needed for successful classic LMA insertion [10]. Another report showed that the EC₅₀ of propofol required for laryngeal tube insertion was 14 % lower than that required for classic LMA insertion [26]. Such findings suggest that the extent of airway reactivity can be affected by the shape and rigidity. In this study, the EC₅₀ of propofol needed for successful i-gel insertion without muscle relaxants was 6.8 µg/mL. The i-gel has a unique noninflatable cuff that is bulkier than that of the classic or Pro-Seal LMA before inflation. The i-gel cuff is slightly harder than the inflatable LMA cuff. We believe that the i-gel cuff is the

Fig. 3 BIS and hemodynamic variables. Base, L2, L4, L6, L8, and L10 indicate before loading and 2, 4, 6, 8, 10 min after loading of dexmedetomidine (group D) or saline (group C), respectively. P1, P2, P3, P4, P5 indicate 1, 2, 3, 4, 5 min after propofol infusion, respectively. A11, A12, A13 indicate 1, 2, 3 min after i-gel insertion, respectively. MBP mean blood pressure, HR heart rate, BIS bispectral index. * $p < 0.01$ compared with control group



main factor responsible for the airway reactivity, which is a key factor in successful i-gel insertion.

DEX is also known to be effective in reducing airway and reflex response during intubation [12, 14–16] and extubation [27, 28]. In this study, the major obstacles to successful i-gel insertion were inadequate jaw relaxation and increased airway reactivity. The i-gel insertion conditions were comparable between the two groups, but preoperative DEX administration decreased the EC₅₀ of propofol required for successful i-gel insertion by 53 %. Such findings suggest that DEX may increase jaw relaxation and reduce airway reactivity during i-gel insertion. Consistent with our result, a previous study demonstrated that preoperative oral clonidine at 5 µg/kg dramatically reduced the EC₅₀ of propofol needed for LMA insertion in male patients [9]. Another report indicated that the extent of the reduction of the propofol concentration for LMA insertion was ~25 % with oral clonidine premedication at 5 µg/kg [29]. We believe that the sedative and analgesic properties of DEX help to decrease the EC₅₀ of propofol for i-gel insertion without muscle relaxants.

In this study, the EC₀₅ of propofol for successful i-gel insertion was 7.78 µg/mL when anesthesia was induced with only propofol. In clinical practice, such high-dose

propofol administration is not routinely used for anesthetic induction because anesthetic induction with high-dose propofol is associated with increased episodes of hypotension [30]. This study showed that preoperative DEX decreased the incidence of hypotension during anesthetic induction and after i-gel insertion by reducing the high propofol concentrations required for anesthetic induction. In addition, because low-dose DEX decreases MBP and HR due to its sympatholytic effect [11, 31], preoperative DEX administration can blunt the sympathoadrenal responses to i-gel insertion. Therefore, it is reasonable to administrate DEX before anesthetic induction for hemodynamic stabilization during the peri-insertion period of i-gel.

In general, propofol is the first-choice induction agent when supraglottic airway devices are inserted without the use of muscle relaxants because it substantially reduces airway reactivity [7, 8]. Additionally, a previous study showed that propofol in combination with butorphanol provided absolute jaw relaxation and excellent LMA insertion conditions [32]. For this reason, propofol was used as an induction agent in this study. Muscle relaxants may be helpful in blocking body movements and reducing the cough and gag reflex caused by i-gel insertion. However, muscle relaxants are not always necessary for successful i-gel insertion.

Opioids may improve the i-gel insertion conditions by deepening the anesthetic level; however, they are associated with muscle rigidity, delayed anesthetic recovery, and post-operative apnea, especially after short general anesthesia [33–35].

High-dose DEX administration or rapid administration of DEX can lead to tachycardia and bradycardia because of sudden exogenous catecholamine release [36, 37]. DEX 0.5–1 µg/kg loading over 10–15 min and subsequent continuous infusion of 0.5–1.0 µg/kg/min is generally recommended during general anesthesia [38, 39]. However, pre-operative single administration of DEX 0.5–1 µg/kg over 10 min without continuous infusion is also a simple, easy, and effective adjuvant for general anesthesia [40, 41]. Previous studies on intubation-related hemodynamic response showed that preanesthetic single administration of DEX 1 µg/kg over 10–15 min effectively blunted an increase in MBP and HR after laryngoscopic intubation [15, 42, 43]. Therefore, in this study, DEX of 1 µg/kg was preoperatively administered over 10 min.

There were several limitations to this study. First, patients with normal airways were mainly included in this study. Therefore, the propofol concentration required for successful i-gel insertion was not investigated in patients with difficult airways or risk factors for i-gel insertion failure. A recent study identified male sex, old age, poor dentition, and impaired mandibular subluxation as risk factors for i-gel insertion failure [44]. Second, the propofol EC₉₅ rather than the propofol EC₅₀ for successful i-gel insertion is of clinical interest. A caution is needed in interpreting our results, especially the propofol EC₉₅ because the value is estimated from Probit analysis, not measured directly. Third, initial effect-site propofol concentration was different between two groups in this study. Furthermore, the propofol concentration was never overlapped in either group during the study period. Therefore, although there was an effort to blind the investigator to the group assignment, this study was not thoroughly double-blinded, which may cause a bias. Finally, although opioids are commonly used during anesthetic induction, the effect of opioids used during anesthetic induction on the propofol EC₅₀ for successful i-gel insertion was not investigated in this study because we focused on the effect of preoperative DEX on the propofol EC₅₀ for successful i-gel insertion. A previous report indicated that remifentanyl significantly reduced the EC₅₀ of propofol required for successful insertion of supraglottic airway devices [18].

In conclusion, this investigation demonstrated that the EC₅₀ of propofol required for successful i-gel insertion without muscle relaxants was 6.75 µg/mL and that preoperative DEX administration reduced the EC₅₀ of propofol significantly.

Conflict of interest None.

References

1. Haske D, Schempf B, Gaier G, Niederberger C. Performance of the i-gel during pre-hospital cardiopulmonary resuscitation. *Resuscitation*. 2013;84:1229–32.
2. Donaldson W, Michalek P. The use of an i-gel supraglottic airway for the airway management of a patient with subglottic stenosis: a case report. *Minerva Anesthesiol*. 2010;76:369–72.
3. Emmerich M, Tiesmeier J. The i-gel supraglottic airway: a useful tool in case of difficult fiberoptic intubation. *Minerva Anesthesiol*. 2012;78:1169–70.
4. Kim YL, Seo DM, Shim KS, Kim EJ, Lee JH, Lee SG, Ban JS. Successful tracheal intubation using fiberoptic bronchoscope via an i-gel supraglottic airway in a pediatric patient with Goldenhar syndrome – a case report. *Korean J Anesthesiol*. 2013;65:61–5.
5. Kosucu M, Eroglu A, Besir A, Cansu A. Using Proseal LMA and i-gel for difficult airway management in patient with diffuse tracheal stenosis and pulmonary artery sling. *Bratisl Lek Listy*. 2013;114:418–20.
6. Ruetzler K, Gruber C, Nabecker S, Wohlfarth P, Priemayr A, Frass M, Kimberger O, Sessler DI, Roessler B. Hands-off time during insertion of six airway devices during cardiopulmonary resuscitation: a randomised manikin trial. *Resuscitation*. 2011;82:1060–3.
7. Barker P, Langton JA, Wilson IG, Smith G. Movements of the vocal cords on induction of anaesthesia with thiopentone or propofol. *Br J Anaesth*. 1992;69:23–5.
8. Brown GW, Patel N, Ellis FR. Comparison of propofol and thiopentone for laryngeal mask insertion. *Anaesthesia*. 1991;46:771–2.
9. Higuchi H, Adachi Y, Arimura S, Nitahara K, Satoh T. Oral clonidine premedication reduces the EC₅₀ of propofol concentration for laryngeal mask airway insertion in male patients. *Acta Anaesthesiol Scand*. 2002;46:372–7.
10. Kodaka M, Okamoto Y, Koyama K, Miyao H. Predicted values of propofol EC₅₀ and sevoflurane concentration for insertion of laryngeal mask Classic and ProSeal. *Br J Anaesth*. 2004;92:242–5.
11. Farag E, Argalious M, Abd-Elsayed A, Ebrahim Z, Doyle DJ. The use of dexmedetomidine in anesthesia and intensive care: a review. *Curr Pharm Des*. 2012;18:6257–65.
12. Keniya VM, Ladi S, Naphade R. Dexmedetomidine attenuates sympathoadrenal response to tracheal intubation and reduces perioperative anaesthetic requirement. *Indian J Anaesth*. 2011;55:352–7.
13. Kunisawa T, Ueno M, Kurosawa A, Nagashima M, Hayashi D, Sasakawa T, Suzuki A, Takahata O, Iwasaki H. Dexmedetomidine can stabilize hemodynamics and spare anesthetics before cardiopulmonary bypass. *J Anesth*. 2011;25:818–22.
14. Lee JH, Kim H, Kim HT, Kim MH, Cho K, Lim SH, Lee KM, Kim YJ, Shin CM. Comparison of dexmedetomidine and remifentanyl for attenuation of hemodynamic responses to laryngoscopy and tracheal intubation. *Korean J Anesthesiol*. 2012;63:124–9.
15. Yildiz M, Tavlan A, Tuncer S, Reisli R, Yosunkaya A, Otelcioglu S. Effect of dexmedetomidine on haemodynamic responses to laryngoscopy and intubation: perioperative haemodynamics and anaesthetic requirements. *Drugs R D*. 2006;7:43–52.
16. Scher CS, Gitlin MC. Dexmedetomidine and low-dose ketamine provide adequate sedation for awake fiberoptic intubation. *Can J Anaesth*. 2003;50:607–10.

17. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C, Goodale DB, Youngs EJ. The influence of age on propofol pharmacodynamics. *Anesthesiology*. 1999;90:1502–16.
18. Park HJ, Lee JR, Kim CS, Kim SD, Kim HS. Remifentanyl halves the EC50 of propofol for successful insertion of the laryngeal mask airway and laryngeal tube in pediatric patients. *Anesth Analg*. 2007;105:57–61.
19. Wharton NM, Gibbison B, Gabbott DA, Haslam GM, Muchatuta N, Cook TM. i-gel insertion by novices in manikins and patients. *Anaesthesia*. 2008;63:991–5.
20. Dixon WJ. Staircase bioassay: the up-and-down method. *Neurosci Biobehav Rev*. 1991;15:47–50.
21. Choi SC. Interval estimation of the LD50 based on an up-and-down experiment. *Biometrics*. 1990;46:485–92.
22. Jung H, Choi SC. Sequential method of estimating the LD50 using a modified up-and-down rule. *J Biopharm Stat*. 1994;4:19–30.
23. Pace NL, Stylianou MP. Advances in and limitations of up-and-down methodology: a precis of clinical use, study design, and dose estimation in anesthesia research. *Anesthesiology*. 2007;107:144–52.
24. Casati A, Fanelli G, Casaletti E, Cedrati V, Veglia F, Torri G. The target plasma concentration of propofol required to place laryngeal mask versus cuffed oropharyngeal airway. *Anesth Analg*. 1999;88:917–20.
25. Taylor IN, Kenny GN. Requirements for target-controlled infusion of propofol to insert the laryngeal mask airway. *Anaesthesia*. 1998;53:222–6.
26. Richebe P, Rivalan B, Baudouin L, Sesay M, Sztark F, Cros AM, Maurette P. Comparison of the anaesthetic requirement with target-controlled infusion of propofol to insert the laryngeal tube vs. the laryngeal mask. *Eur J Anaesthesiol*. 2005;22:858–63.
27. Guler G, Akin A, Tosun Z, Eskitascoglu E, Mizrak A, Boyaci A. Single-dose dexmedetomidine attenuates airway and circulatory reflexes during extubation. *Acta Anaesthesiol Scand*. 2005;49:1088–91.
28. Aksu R, Akin A, Bicer C, Esmoğlu A, Tosun Z, Boyaci A. Comparison of the effects of dexmedetomidine versus fentanyl on airway reflexes and hemodynamic responses to tracheal extubation during rhinoplasty: a double-blind, randomized, controlled study. *Curr Ther Res Clin Exp*. 2009;70:209–20.
29. Goyagi T, Tanaka M, Nishikawa T. Oral clonidine premedication reduces propofol requirement for laryngeal mask airway insertion. *Can J Anaesth*. 2000;47:627–30.
30. Dhungana Y, Bhattarai BK, Bhadani UK, Biswas BK, Tripathi M. Prevention of hypotension during propofol induction: a comparison of preloading with 3.5% polymers of degraded gelatin (Haemaccel) and intravenous ephedrine. *Nepal Med Coll J*. 2008;10:16–9.
31. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. *Anesthesiology*. 2000;93:1345–9.
32. Gupta A, Kaur S, Attri JP, Saini N. Comparative evaluation of ketamine-propofol, fentanyl-propofol and butorphanol-propofol on haemodynamics and laryngeal mask airway insertion conditions. *J Anaesthesiol Clin Pharmacol*. 2011;27:74–8.
33. Bailey PL, Streisand JB, East KA, East TD, Isern S, Hansen TW, Posthuma EF, Rozendaal FW, Pace NL, Stanley TH. Differences in magnitude and duration of opioid-induced respiratory depression and analgesia with fentanyl and sufentanil. *Anesth Analg*. 1990;70:8–15.
34. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. *Anesthesiology*. 2010;112:226–38.
35. Christian CM 2nd, Waller JL, Moldenhauer CC. Postoperative rigidity following fentanyl anesthesia. *Anesthesiology*. 1983;58:275–7.
36. Grant SA, Breslin DS, MacLeod DB, Gleason D, Martin G. Dexmedetomidine infusion for sedation during fiberoptic intubation: a report of three cases. *J Clin Anesth*. 2004;16:124–6.
37. Snapir A, Posti J, Kentala E, Koskenvuo J, Sundell J, Tuunanen H, Hakala K, Scheinin H, Knuuti J, Scheinin M. Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. *Anesthesiology*. 2006;105:902–10 quiz 1069–70.
38. Hong JY, Kim WO, Yoon Y, Choi Y, Kim SH, Kil HK. Effects of intravenous dexmedetomidine on low-dose bupivacaine spinal anaesthesia in elderly patients. *Acta Anaesthesiol Scand*. 2012;56:382–7.
39. Kunisawa T, Nagata O, Nagashima M, Mitamura S, Ueno M, Suzuki A, Takahata O, Iwasaki H. Dexmedetomidine suppresses the decrease in blood pressure during anesthetic induction and blunts the cardiovascular response to tracheal intubation. *J Clin Anesth*. 2009;21:194–9.
40. Basar H, Akpınar S, Dogancı N, Buyukkocak U, Kaymak C, Sert O, Apan A. The effects of preanesthetic, single-dose dexmedetomidine on induction, hemodynamic, and cardiovascular parameters. *J Clin Anesth*. 2008;20:431–6.
41. Shin HW, Yoo HN, Kim DH, Lee H, Shin HJ, Lee HW. Preanesthetic dexmedetomidine 1 microg/kg single infusion is a simple, easy, and economic adjuvant for general anesthesia. *Korean J Anaesthesiol*. 2013;65:114–20.
42. Menda F, Koner O, Sayin M, Ture H, Imer P, Aykac B. Dexmedetomidine as an adjunct to anesthetic induction to attenuate hemodynamic response to endotracheal intubation in patients undergoing fast-track CABG. *Ann Card Anaesth*. 2010;13:16–21.
43. Reddy SV, Balaji D, Ahmed SN. Dexmedetomidine versus esmolol to attenuate the hemodynamic response to laryngoscopy and tracheal intubation: a randomized double-blind clinical study. *Int J Appl Basic Med Res*. 2014;4:95–100.
44. Theiler L, Gutzmann M, Kleine-Brueggene M, Urwyler N, Kaempfen B, Greif R. i-gel supraglottic airway in clinical practice: a prospective observational multicentre study. *Br J Anaesth*. 2012;109:990–5.